Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma

European Journal of Cancer

Volumn 33, Issue 12, 1997, Pages 2101-2105

  Combaret, V ^a   Gross, N ^b   Lasset, C ^a   Frappaz, D ^a   Beretta Brognara, C ^b   Philip, T ^a   Beck, D ^b   Favrot, M C ^a  

^a CENTRE LÉON BÉRARD   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

CD44 neuroblastoma; Prognosis

Indexed keywords

HERMES ANTIGEN;

ANTIGEN EXPRESSION; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CONFERENCE PAPER; GANGLIONEUROMA; GENE AMPLIFICATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS;

AGE FACTORS; ANTIGENS, CD44; ANTIGENS, NEOPLASM; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENES, MYC; HUMANS; INFANT; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS;

EID: 0031427274     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00236-0     Document Type: Conference Paper

References (15)

1. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993, 11, 1466-1477.
2. Brodeur GM, Azar C, Brother M, et al. Neuroblastoma: Effect of genetic factors on prognosis and treatment. Cancer 1992, 70, 1685-1694.
3. Philip T, Zucker JM, Bernard JL, et al. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup. J Clin Oncol 1991, 9, 1037-1044.
4. Favrot M. C., Combaret V., Lasset C. CD44: a new prognostic marker for neuroblastoma. N Engl J Med. 329:1993;1965.
5. Gross N., Beretta C., Peruisseau G., et al. CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation. Cancer Res. 54:1994;4238-4242.
6. Combaret V, Gross N, Lasset C, et al. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 1996, 14, 25-34.
7. Philip T, Bernard JL, Zucker JM, et al. High dose chemotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over one year of age. J Clin Oncol 1989, 5, 266-271.
8. Zucker JM, Philip T, Bernard JL, et al. Single or double consolidation treatment according to remission status after initial therapy in metastatic neuroblastoma: first results of LMCE3 study in 40 patients. In Evans AE, D'Angio GJ, Knudson AG Jr, Seeder RC, eds. Advances in Neuroblastoma Research. New-York, Wiley-Liss Inc., 1991, 543-551.
9. Thiesse P, Kaemmerlen P, Bouffet E, et al. Percutaneous fine needle guided biopsies of the primary tumour in extensive neuroblastoma. In Evans AE, D'Angio GJ, Knudson AG Jr, Seeder RC, eds. Advances in Neuroblastoma Research. New-York, Wiley-Liss Inc., 1991, 503-507.
10. Favrot MC, Combaret V, Goillot E, et al. Expression of leucocyte adhesion molecules on 66 clinical neuroblastoma specimens. Int J Cancer 1991, 48, 502-510.
11. Combaret V, Wang Q, Favrot MC, et al. Clinical value of N-myc oncogene amplification in 52 patients with neuroblastoma included in recent therapeutic protocols. Eur J Cancer Clin Oncol 1989, 24, 1607-1612.
12. Pesando J. M., Hoffman P., Abed M. Antibody-induced antigenic modulation is antigen dependent: characterization of 22 proteins on a malignant human B cell line. J Immunol. 137:1986;3689-3695.
13. Dalchau R., Kirkley R., Fabre J. W. Monoclonal antibody to a human brain-granulocyte T lymphocyte antigen probably homologous to the W3/13 antigen of the rat. Eur J Immunol. 10:1980;745-749.
14. Kaplan E. S., Meier P. Non parametric estimations from incomplete observation. Ann Stat Assoc. 53:1958;457-481.
15. Mantel H., Haenzel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:1959;719-748.